Results 261 to 270 of about 1,574,312 (309)
Some of the next articles are maybe not open access.

Overall Survival for Osimertinib Wows

Cancer Discovery, 2023
Abstract The final overall survival (OS) results for the ADAURA trial show that osimertinib reduces the risk of death by 51% in patients with EGFR-mutated non–small cell lung cancer. For stage II or IIIA disease, the 5-year OS was 85% in patients who received osimertinib and 73% in the control group.
openaire   +2 more sources

Concordance index: Surrogacy of progression-free survival for overall survival

Contemporary Clinical Trials, 2021
In oncology clinical trials, the primary endpoint is often time to an event of clinical interest, e.g., time to disease progression or time to death. As a result, progression-free survival (PFS: the time from initiation of treatment till disease progression or death whichever occurs first) and overall survival (OS: the time from initiation of treatment
Yiwei, Fan, Guosheng, Yin
openaire   +2 more sources

Overall survival in older patients with cancer

BMJ Supportive & Palliative Care, 2018
ObjectivesA growing number of patients with cancer are older adults. We sought to identify the predictors for overall survival (OS) in older adults with solid tumour and haematological malignancies between January 2013 and December 2016.MethodsRetrospective cohort study.
Beatrice J Edwards   +11 more
openaire   +2 more sources

Brain Metastases: Surgical Treatment and Overall Survival

World Neurosurgery, 2017
Brain metastases occur in 10%-40% of patients with cancer and are more common than primary brain tumors (30%-40%); their incidence is growing because of improvements in control of systemic disease, better radiologic detection, and prolonged survival. Modern treatment of brain metastases has dramatically changed the expected prognosis.
D(')Andrea, G.   +4 more
openaire   +6 more sources

Overall Treatment and Survival

1989
The overall pattern of gastric cancer presentation, treatment and outcome is described in this chapter. The results are described for all patients for the whole period and also by quinquennia or decades in order to evaluate changes occurring during the study period. Presentation is assessed by site and stage. The type of treatment is evaluated overall,
John W. L. Fielding   +4 more
openaire   +1 more source

Overall survival in patients with metastatic melanoma

Current Medical Research and Opinion, 2015
Patients with regionally or distantly metastatic melanoma have poor long-term prognosis. The objective of this analysis was to describe survival rates among patients diagnosed with unresectable stage IIIB/C or stage IV melanoma.Using data from the Surveillance, Epidemiology, and End Results (SEER) database, patients diagnosed with unresectable stage ...
Xue, Song   +5 more
openaire   +2 more sources

Recombinant human erythropoietin and overall survival

Current Oncology Reports, 2005
Although a trend was seen for increased thromboembolic events in patients treated with erythropoietin, there was also a trend for improved survival times in such patients.
openaire   +2 more sources

Tumor locations significantly affect disease free survival and overall survival.

Journal of Clinical Oncology, 2015
e12590 Background: The association of tumor quadrants and survival times has been investigated in limited previous retrospective trials.
ŞENDUR, MEHMET ALİ NAHİT   +8 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy